Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHF 5993 versus tiotropium-based therapy in COPD
2013-000063-91Phase 3Completed
- Sponsor
- Chiesi Farmaceutici S.p.A.
- Start
- Oct 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of beclomethasone dipropionate, formoterol, glycopyrronium and tiotropium in chronic obstructive pulmonary disease (COPD) (3 arms), sponsored by Chiesi Farmaceutici S.p.A. Primary endpoint: Moderate and severe COPD exacerbation rate. Started Oct 2013; status: completed.
02
Drugs
beclomethasone dipropionateformoterolglycopyrroniumtiotropium
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2013-000063-91.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-000063-91.